STOCK TITAN

Telomir picks Linical for Telomir-Zn breast cancer trial

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. (TELO) selected Linical to support its FDA-cleared Phase 1/2 clinical trial of investigational Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer. The companies executed a Master Services Agreement and clinical trial Work Order, with clinical initiation targeted for the first quarter of 2027. The monotherapy study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity. Linical has more than two decades of oncology clinical-development experience, approximately half in early-phase studies. Telomir says Telomir-Zn is designed to regulate intracellular metal homeostasis and potentially reactivate silenced tumor-suppressor genes; preclinical research demonstrated antitumor activity in TNBC models.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Oncology clinical-development experience More than two decades Linical experience, including breast cancer and other solid tumors
Early-phase share of oncology experience Approximately half Linical oncology experience
Clinical trial phase Phase 1/2 FDA-cleared Telomir-Zn monotherapy study in advanced or metastatic TNBC
Targeted clinical initiation First quarter of 2027 Telomir-Zn clinical trial
contract research organization technical
"Linical, a global contract research organization (CRO)"
A contract research organization (CRO) is an outside company hired to run medical and scientific work for drug, device or biotech developers—like an experienced project manager and lab team that companies rent instead of building in-house. Investors care because CROs influence development speed, quality and cost: delays or successes in trials affect client spending, regulatory risk and ultimately revenues for both the sponsor and the CRO.
Investigational New Drug (IND) application regulatory
"clearance of Telomir’s Investigational New Drug (IND) application"
An investigational new drug (IND) application is a formal request submitted to a drug regulator asking permission to begin testing a new medicine in people. It compiles lab results, manufacturing details and proposed human trial plans so regulators can judge safety before human studies start; for investors, an accepted IND is a key milestone that opens the clinical development pathway and can materially change a company’s risk profile and potential value, like getting a license to road-test a prototype.
triple-negative breast cancer medical
"patients with advanced or metastatic triple-negative breast cancer"
Triple-negative breast cancer is a type of breast cancer that lacks three common markers used to identify and treat the disease effectively. Because it doesn’t respond to some targeted therapies, it can be more difficult to treat and may have a more aggressive progression. This impacts the development of new treatments and can influence the outlook for healthcare companies involved in cancer research and pharmaceuticals.
pharmacokinetics medical
"safety, tolerability, pharmacokinetics, pharmacodynamics"
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
pharmacodynamics medical
"pharmacokinetics, pharmacodynamics, and preliminary antitumor activity"
Pharmacodynamics is how a drug actually affects the body — the strength, type and duration of its effects and the relationship between dose and response. Think of it like how turning a thermostat changes room temperature: it shows what the drug does and how much is needed to get the desired effect. Investors care because these properties drive clinical success, dosing convenience, safety profile and competitive advantage, all of which influence commercial potential and regulatory approval.
intracellular metal homeostasis medical
"designed to regulate intracellular metal homeostasis"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will TELO evaluate in its Phase 1/2 trial?

The study will assess safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of Telomir-Zn as a monotherapy in patients with advanced or metastatic triple-negative breast cancer.

How much oncology experience does Linical have?

Linical has more than two decades of oncology clinical-development experience, including breast cancer and other solid tumors. Approximately half of its oncology experience is concentrated in early-phase studies, and its capabilities span Phase 1 through Phase 4 clinical development.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001971532 0001971532 2026-11-18 2026-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 18, 2026

 

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Florida 001-41952   87-2606031
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

100 SE 2nd St, Suite 2000, #1009

Miami, Florida 33131

(Address of Principal Executive Offices)

 

Registrant’s telephone number, including area code: (786) 396-6723

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, no par value   TELO   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On November 18, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has selected Linical, a global contract research organization (“CRO”) with extensive oncology experience, to support its U.S. Food and Drug Administration-cleared Phase 1/2 clinical trial evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (“TNBC”).

 

Linical has more than two decades of experience supporting oncology clinical development, including breast cancer and other solid tumors, with approximately half of its oncology experience concentrated in early-phase studies. Its oncology capabilities span Phase 1 through Phase 4 clinical development, encompassing clinical trial startup, investigator-site coordination, patient recruitment, clinical monitoring, project management, biometrics, and regulatory support.

 

The Company has executed a Master Services Agreement and clinical trial Work Order with Linical, establishing the operational framework to advance the study toward clinical initiation, targeted for the first quarter of 2027.

 

Cautionary Note Regarding Forward-Looking Statements

 

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, efficacy, anticipated clinical development, commercialization prospects, market opportunity and future development of Telomir-Zn, including its potential applications in oncology and other disease indications, and the Company’s other research and development programs.

 

These forward-looking statements are based on current expectations, estimates, forecasts and projections, as well as management’s current beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development; the initiation, timing, progress and results of clinical trials and other studies; the ability to recruit and enroll patients in clinical trials; the safety and efficacy of Telomir-Zn; the Company’s ability to obtain and maintain regulatory approvals; the timing and outcome of regulatory submissions and interactions with regulatory authorities; reliance on third-party manufacturers, contract research organizations and other service providers; intellectual property protection; the Company’s ability to obtain additional financing; commercialization and market acceptance of the Company’s product candidates, if approved; competition; market conditions; and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange Commission (“SEC”).

 

Forward-looking statements contained in this report speak only as of the date of this report, and the Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

 

Investors are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding these and other risks and uncertainties is contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K and subsequent filings, available at www.sec.gov and in the Investors section of the Company’s website at www.telomirpharma.com. Forward-looking statements should be considered in light of these risks and uncertainties.

 

Item 9.01 Financial Statements and Other Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release of Telomir Pharmaceuticals, Inc., dated November 18, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TELOMIR PHARMACEUTICALS, INC.
     
Dated: November 18, 2026 By: /s/ Erez Aminov
  Name: Erez Aminov
  Title: Chief Executive Officer

 

 

 

 

Exhibit 99.1

 

Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer

 

Global CRO Brings Extensive Oncology Experience, Including Breast Cancer and Early-Phase Clinical Development

 

Executed Clinical Trial Agreements Support Targeted Clinical Initiation in the First Quarter of 2027

 

MIAMI, Nov. 18, 2026 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (“Telomir” or the “Company”), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer, today announced that it has selected Linical, a global contract research organization (CRO) with extensive oncology experience, to support its FDA-cleared Phase 1/2 clinical trial evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (TNBC).

 

Telomir has executed a Master Services Agreement and clinical trial Work Order with Linical, establishing the operational framework to advance the study toward clinical initiation, targeted for the first quarter of 2027.

 

The engagement follows the U.S. Food and Drug Administration’s clearance of Telomir’s Investigational New Drug (IND) application and represents an important operational milestone as the Company advances toward clinical execution.

 

“Following FDA clearance of our IND, our priority has been to establish the clinical infrastructure necessary to advance Telomir-Zn into patients,” said Erez Aminov, Chairman and Chief Executive Officer of Telomir Pharmaceuticals. “We selected Linical for its extensive oncology experience, including breast cancer and early-phase clinical development. With our clinical trial agreements now executed, we are focused on advancing toward clinical initiation in the first quarter of 2027 and evaluating the potential of our novel oral epigenetic therapy in patients with triple-negative breast cancer.”

 

“We are pleased to partner with Telomir Pharmaceuticals as it prepares to evaluate Telomir-Zn in patients with triple-negative breast cancer,” said Clareece West, President at Linical. “Our CRO team brings extensive experience in oncology and early-phase clinical development to this partnership, and we look forward to helping Telomir advance their important clinical program.”

 

Linical’s Oncology and Breast Cancer Expertise

 

Linical is a global CRO with more than two decades of experience supporting oncology clinical development, including breast cancer and other solid tumors. Linical has completed numerous oncology clinical trials, with approximately half of its oncology experience concentrated in early-phase studies.

 

 

 

 

Linical’s oncology capabilities span Phase 1 through Phase 4 clinical development, encompassing clinical trial startup, investigator-site coordination, patient recruitment, clinical monitoring, project management, biometrics, and regulatory support.

 

Linical’s established oncology infrastructure and experience in breast cancer research align with the operational needs of Telomir’s planned clinical program, supporting the company’s preparations for clinical evaluation of Telomir-Zn.

 

Advancing a Novel Oral Epigenetic Therapy for Triple-Negative Breast Cancer

 

Telomir-Zn is an investigational oral epigenetic therapy designed to regulate intracellular metal homeostasis and potentially reactivate silenced tumor suppressor genes involved in controlling cancer growth.

 

The therapeutic approach is based on the role of intracellular metals, particularly iron, in regulating epigenetic processes. Certain cancers, including triple-negative breast cancer, exhibit increased dependence on iron-related biological pathways which support their uncontrolled growth. By modulating intracellular metal availability, Telomir-Zn inhibits several key iron-dependent epigenetic enzymes, thereby potentially restoring tumor suppressor gene functions.

 

Preclinical research has demonstrated antitumor activity in TNBC models, supporting further investigation of Telomir-Zn in cancers with elevated iron dependency.

 

In this upcoming FDA-cleared Phase 1/2 clinical study, Telomir will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of Telomir-Zn as a monotherapy in patients with advanced or metastatic TNBC.

 

The Company is advancing clinical trial preparations with Linical and continues to target clinical initiation in the first quarter of 2027.

 

About Linical

 

Linical is a global contract research organization providing comprehensive clinical development services to pharmaceutical and biotechnology companies. With operations across North America, Europe, and Asia-Pacific, Linical supports clinical trials across multiple therapeutic areas (including oncology, neurology, immunology, endocrinology, and rare disease) with a significant focus on early-phase clinical development.

For more information, visit www.linical.com.

 

About Telomir Pharmaceuticals

 

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer.

 

For more information, please visit https://telomirpharma.com/.

 

 

 

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target,” and other words of similar meaning, although not all forward-looking statements include these words.

 

Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s other product candidates. Forward-looking statements may also include statements regarding the anticipated closing of the financing described herein, the expected proceeds from and intended use of such proceeds, the significance of the published preclinical findings, the relevance of such findings to the Company’s oncology development programs, the advancement of the Company’s Phase 1/2 TNBC clinical trial, and the potential applicability of Telomir-Zn across multiple disease areas.

 

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission (“SEC”).

 

Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

 

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the “Investors” section of our website, for a discussion of these and other risks and uncertainties.

 

Contact Information

 

Krystina Quintana
Email: info@telomirpharma.com
Phone: (786) 396-6723

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading